LAUSR

INTRODUCTION HFpEF is a leading cause of death whose burden is projected to increase in the coming decades. The aim of this paper is to interrogate the relationship between levels of circulating galectin-3, an emerging risk factor for cardiovascular disease, and the clinical diagnosis of HFpEF. METHODS The authors reviewed peer-reviewed literature and 18 studies met inclusion criteria. Study characteristics, study outcome definitions, assay characteristics, main findings, and measures of association were tabulated and summarized. RESULTS Five studies found significant associations between galectin-3 and HFpEF diagnosis compared to healthy controls, and one did not. Five studies found significant associations between levels of circulating galectin-3 and severity of diastolic dysfunction. Three studies found significant associations between galectin-3 and all-cause mortality or rehospitalization. Two studies found levels of circulating galectin-3 to be a statistically significant predictor of later HFpEF onset. Finally, two studies examined whether galectin-3 was associated with incident HFpEF, one found a significant association and the other did not. CONCLUSION Given the paucity of effective therapeutics for HFpEF, galectin-3 shows promise as a possible HFpEF-linked biomarker that may, with further study, inform and predict treatment course to reduce morbidity and mortality.